We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

What the COVID-19 Pandemic Taught Us About Flexibility in Vaccine Manufacturing

Article   May 04, 2021 | Amélie Boulais, Sartorius

 
What the COVID-19 Pandemic Taught Us About Flexibility in Vaccine Manufacturing
 
 
Advertisement
 

RELATED ARTICLES

Teach Me in 10 Hub Page

Article

At Technology Networks we understand the importance of time. That's why we've launched Teach Me in 10 a video series that challenges scientists to present and summarize their research area, a scientific concept, or technology in ten minutes or less.

READ MORE

Unintended Consequences: The Risks of Vacating COVID-19 Vaccine Patents

Article

In this op-ed piece, Michael S. Kinch, director of the Centers for Research Innovation in Biotechnology and Drug Discovery at Washington University in St. Louis, explores the issue of eliminating patent protection for COVID-19 vaccines.

READ MORE

Toxicity Studies in Vaccine Clinical Development and Registration

Article

Before the safety and efficacy of a new vaccine can be evaluated in a Phase I clinical trial with human subjects, it must first undergo non-clinical safety evaluation in animal models. This article explores the full process.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Biopharma Cancer Research Cell Science Diagnostics Drug Discovery Genomics Research Informatics Proteomics & Metabolomics Neuroscience Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE